Sorafenib in non-small cell lung cancer

Bibliography

• Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61(4):212-36
   PubMed Web of Science ®Google Scholar
• Wahbah M, Boroumand N, Castro C, Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol 2007;11(2):89-96
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
   PubMed Web of Science ®Google Scholar
• Spiro SG, Rudd RM, Souhami RL, Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004;59(10):828-36
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• de Marinis F, Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 2008;13(Suppl 1):14-20
   Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Hanna N, Fossella F, The differential efficacy of pemetrexed according to nsclc histology: a review of two phase iii studies. Oncologist 2009;14(3):253-63
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374(9699):1432-40
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Randomized phase ii trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-91
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39
   PubMed Web of Science ®Google Scholar
• Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12(24):7232-41
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, von Pawel J, Egfr expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 flex study. Lancet Oncol 2012;13(1):33-42
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Solomon BJ, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring alk gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12(11):1004-12
   PubMed Web of Science ®Google Scholar
• Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12(2):175-80
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is kras a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010;28(31):4769-77
   PubMed Web of Science ®Google Scholar
• Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235(4787):442-7
   PubMed Web of Science ®Google Scholar
• Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267(16):10931-4
   PubMed Web of Science ®Google Scholar
• Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol 1999;6(8):R217-24
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-57
   PubMed Web of Science ®Google Scholar
• Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996;32A(14):2451-60
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001;28(6):536-42
   PubMed Web of Science ®Google Scholar
• Shibuya M, Claesson-Welsh L. Signal transduction by vegf receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006;312(5):549-60
   PubMed Web of Science ®Google Scholar
• Uyttendaele H, Ho J, Rossant J, Kitajewski J. Vascular patterning defects associated with expression of activated notch4 in embryonic endothelium. Proc Natl Acad Sci USA 2001;98(10):5643-8
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase iii trial (avail). Ann Oncol 2010;21(9):1804-9
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen AD, combined inhibition of vegf and pdgf signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18(2):338-40
   PubMed Web of Science ®Google Scholar
• Lu C, Kamat AA, Lin YG, Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007;13(14):4209-17
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, Azd2171, a pan-vegf receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of vegf signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the raf/mek/erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Wu S, Robert C, Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13(9):1001-11
   PubMed Web of Science ®Google Scholar
• Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 2011;30(32):3477-88
   PubMed Web of Science ®Google Scholar
• Heidorn SJ, Milagre C, Whittaker S, Kinase-dead braf and oncogenic ras cooperate to drive tumor progression through craf. Cell 2010;140(2):209-21
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the braf gene in human cancer. Nature 2002;417(6892):949-54
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T, Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353(20):2135-47
   PubMed Web of Science ®Google Scholar
• Kemmer K, Corless CL, Fletcher JA, Kit mutations are common in testicular seminomas. Am J Pathol 2004;164(1):305-13
   PubMed Web of Science ®Google Scholar
• Paschka P, Marcucci G, Ruppert AS, Adverse prognostic significance of kit mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a cancer and leukemia group b study. J Clin Oncol 2006;24(24):3904-11
   PubMed Web of Science ®Google Scholar
• Kindler T, Lipka DB, Fischer T. Flt3 as a therapeutic target in aml: still challenging after all these years. Blood 2010;116(24):5089-102
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Sorafenib blocks the raf/mek/erk pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model plc/prf/5. Cancer Res 2006;66(24):11851-8
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Chien DS. Bay 43-9006: preclinical data. Curr Pharm Des 2002;8(25):2255-7
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;56(2):125-34
   Google Scholar
• Dy GK, Hillman SL, Rowland KM Jr, A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: north central cancer treatment group study n0326. Cancer 2010;16(24):5686-93
   Google Scholar
• Flaherty KT, Schiller J, Schuchter LM, A phase i trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008;14(15):4836-42
   PubMed Web of Science ®Google Scholar
• Okamoto I, Miyazaki M, Morinaga R, Phase i clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs 2010;28(6):844-53
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Novello S, von Pawel J, Phase iii study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835-42
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Eisen T, Santoro A, Sorafenib (s) + gemcitabine/cisplatin (gc) vs gc alone in the first-line treatment of advanced non–small cell lung cancer (nsclc): Phase iii nsclc research experience utilizing sorafenib (nexus) trial. Ann Oncol 2010;21(S 8):LBA16
   Google Scholar
• Blumenschein G, Molina J, Lathia C, Phase i dose-escalation study of sorafenib in combination with bevacizumab (b), paclitaxel (p), and carboplatin (c) for the treatment of advanced nonsquamous non-small cell lung cancer (nsclc). ASCO Annu Meeting 2011;2029:7565
   Google Scholar
• Molina J, Dy G, Foster N, A randomized phase ii study of pemetrexed (pem) with or without sorafenib (s) as second-line therapy in advanced non-small cell lung cancer (nsclc) of nonsquamous histology: ncctg n0626 study. ASCO Annu Meeting 2011;2029:7513
   Google Scholar
• Blumenschein GR Jr, Gatzemeier U, Fossella F, Phase ii, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27(26):4274-80
   PubMed Web of Science ®Google Scholar
• Adjei AA, Molina JR, Mandrekar SJ, Phase i trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007;13(9):2684-91
   PubMed Web of Science ®Google Scholar
• Gridelli C, Rossi A, Mongillo F, A randomized phase ii study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. Clin Lung Cancer 2007;8(6):396-8
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Kummar S, Allen D, A phase ii study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (nsclc). ASCO Annu Meeting 2008;2026:19084
   Google Scholar
• Kelly RJ, Rajan A, Force J, Evaluation of kras mutations, angiogenic biomarkers, and dce-mri in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res 2011;17(5):1190-9
   PubMed Web of Science ®Google Scholar
• Schiller J, Lee J, Hanna N, A randomized discontinuation phase ii study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. ASCO Annu Meeting 2008;2026(2020):8014
   Google Scholar
• Kim ES, Herbst RS, Wistuba II, The battle trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (interest): a randomised phase iii trial. Lancet 2008;372(9652):1809-18
   PubMed Web of Science ®Google Scholar
• 60. Spigel DR, Burris HA III, Greco FA, Randomized, double-blind, placebo-controlled, phase ii trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29(18):2582-9
   PubMed Web of Science ®Google Scholar
• Lind JS, Dingemans AM, Groen HJ, A multicenter phase ii study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16(11):3078-87
   PubMed Web of Science ®Google Scholar
• Gridelli C, Morgillo F, Favaretto A, Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase ii study. Ann Oncol 2011;22(7):1528-34
   PubMed Web of Science ®Google Scholar
• Cho B, Kim S, Heo D, A multicenter phase ii study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (nsclc). ASCO Annu Meeting 2010;2028(2015S):7547
   Google Scholar
• Chen HX, Cleck JN. Adverse effects of anticancer agents that target the vegf pathway. Nat Rev Clin Oncol 2009;6(8):465-77
   PubMed Web of Science ®Google Scholar
• Gridelli C, Maione P, Del Gaizo F, Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007;12(2):191-200
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-80
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-7
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with braf v600e mutation. N Engl J Med 2011;364(26):2507-16
   PubMed Web of Science ®Google Scholar
• Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 2011;117(17):3889-99
   PubMed Web of Science ®Google Scholar
• Horn L, Dahlberg SE, Sandler AB, Phase ii study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: eastern cooperative oncology group study e3501. J Clin Oncol 2009;27(35):6006-11
   PubMed Web of Science ®Google Scholar
• Dingemans AM, de Langen AJ, van den Boogaart V, First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase ii study including molecular imaging. Ann Oncol 2011;22(3):559-66
   PubMed Web of Science ®Google Scholar
• Chen Z, Cheng K, Walton Z, A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012;83(7391):613-17
   Google Scholar
• Zhang W, Lee J, Schiller JH, Use of germline polymorphisms in vegf to predict tumor response and progression-free survival in non-small cell lung cancer (nsclc) patients treated with sorafenib: Subset pharmacogenetic analysis of eastern cooperative oncology group (ecog) trial e2501. ASCO Annu Meeting 2010;2028:2015S-7607S
   Google Scholar
• Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer biol ther 2012;13(5):247-63
   PubMed Web of Science ®Google Scholar
• Das M, Wakelee H. Targeting vegf in lung cancer. Expert Opin Ther Targets 2012;16(4):395-406
   PubMed Web of Science ®Google Scholar
• Ellis PM, Al-Saleh K. Multitargeted anti-angiogenic agents and nsclc: Clinical update and. future directions. Crit Rev Oncol Hematol Mar 8, 2012
   PubMed Web of Science ®Google Scholar